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Abstract: Drug resistance is the main obstacle for a successful cancer therapy. There are many mech-
anisms by which cancers avoid drug-mediated death, including alterations in cellular metabolism
and apoptotic programs. Mitochondria represent the cell’s powerhouse and the connection between
carbohydrate, lipid and proteins metabolism, as well as crucial controllers of apoptosis, playing an
important role not only in tumor growth and progression, but also in drug response. Alterations in
tricarboxylic acid cycle (TCA) caused by mutations in three TCA enzymes—isocitrate dehydrogenase,
succinate dehydrogenase and fumarate hydratase—lead to the accumulation of 2-hydroxyglutarate,
succinate and fumarate respectively, collectively known as oncometabolites. Oncometabolites have
pleiotropic effects on cancer biology. For instance, they generate a pseudohypoxic phenotype and
induce epigenetic changes, two factors that may promote cancer drug resistance leading to disease
progression and poor therapy outcome. This review sums up the most recent findings about the role
of TCA-derived oncometabolites in cancer aggressiveness and drug resistance, highlighting possible
pharmacological strategies targeting oncometabolites production in order to improve the efficacy of
cancer treatment.
Keywords: mitochondrial oncometabolites; cancer drug resistance; cancer metabolism
1. Introduction: Mitochondria in Cancer
Treating advanced tumors is still an important challenge because of the concomitant
presence of intrinsic and acquired resistance to the commonly used anti-cancer drugs. Most
advanced tumors share the ability to escape cell death mediated by anticancer drugs, while
continuing their growth and progression. The main mechanisms responsible for drug
resistance, often known as multidrug resistance since it involves multiple drugs with dif-
ferent mechanisms of action, are the reduced drug uptake and accumulation, the increased
drug efflux via membrane transporters that decrease intratumor drug concentration and
cytotoxicity, the efficient mechanisms of DNA repair, the bypass of the DNA damaging
and the cell cycle arrest induced by many chemotherapeutics, the prevalence of survival
pathways over apoptotic pathways, the metabolic reprograming [1]. Inhibition of apoptosis
and metabolic rewiring are strongly correlated with altered mitochondria functions, protect
cancer cells from drug-mediated death inducing drug resistance [2].
Traditionally, the shift from oxidative phosphorylation (OXPHOS) to aerobic glycolysis
is considered a hallmark of cancer, postulated by Otto Von Warburg. This implies that
mitochondria are poorly active in tumors [3]. However, an increasing amount of evidence
demonstrates that, despite several cancers satisfying their energetic requirements using
glycolysis, other tumors—in particular if drug resistant—heavily rely on OXPHOS to fuel
their metabolism [4].
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For many years, mitochondria have been considered only as the energy powerhouse
of the cell. Nonetheless, in addition to their role in generating ATP, mitochondria are key
signaling centers regulating cancer development and progression, including metabolic
reprogramming in response to anticancer drugs. In fact, the mitochondrial oxidative de-
carboxylation of pyruvate, the fatty acid β-oxidation (FAO) and the glutaminolysis are
the key fuel of the tricarboxylic acid (TCA) cycle that sustains production of ATP via
OXPHOS. The mitochondrial intermediate metabolism interconnects amino acid, lipid
and carbohydrate metabolism that are involved in both TCA anaplerotic fluxes, to obtain
energy equivalents, and TCA cataplerotic fluxes towards the synthesis of building blocks
such as proteins and nucleotides. Higher energetic mitochondrial metabolism, higher
anaplerotic and cataplerotic fluxes are hallmarks of drug resistant cancers [5]. Indeed, this
metabolic phenotype replenishes cancer cells either of ATP and building blocks, attenu-
ating the damages of cytotoxic stresses, including chemotherapy. Moreover, blocking the
pyruvate dehydrogenase complex, i.e., the influx of glucose-derived acetyl-CoA into TCA
cycle and/or anaplerotic pathways (such as FAO, glutaminolysis, glutamate oxidative
metabolism, arginine, proline, asparagine, aspartate and phenylalanine catabolism) [6],
buffers production of the reactive oxide species (ROS) by electron transport chain (ETC) [7],
maintaining them below a “danger threshold” and determining the production of low
levels of ROS that train cancer cells to resistance to oxidative stress and chemotherapeutic
drugs, by upregulating antioxidant mechanisms [8].
Beside a key role in energetic metabolism and ROS production, mitochondria regulate
the apoptotic response upon chemotherapy, by decreasing the BCL2/BAX ratio, increasing
the permeabilization of mitochondrial membrane, the opening of mitochondrial permeabil-
ity transition pore and the release of cytochrome c, which activates the apoptosome and the
caspase 9/3 axis [9]. Furthermore, mitochondrial DNA (mtDNA) is frequently mutated in
tumors, spontaneously or upon the damage induced by chemotherapeutic drugs, such as
cisplatin and gemcitabine [10]. Since mtDNA mainly encodes for mitochondrial translation
machinery and ETC complexes, mutations in these key players of OXPHOS may produce
the synthesis of complexes characterized by a defective reduction of electron shuttles
(ubiquinone, cytochrome c), structural components (Fe-S cluster-, cytochrome-containing
proteins) or O2, determining the generation of radical species or ROS. This mitochondrial
dysfunction promotes metabolic alterations, changes the ROS buffering and the balance
between pro-apoptotic and anti-apoptotic signaling, contributing to drug resistance [11].
Genetic alterations of TCA cycle enzymes such as succinate dehydrogenase (SDH),
also shared with complex II of ETC, fumarate hydratase (FH) or isocitrate dehydrogenase
(IDH) lead to the accumulation of the upstream intermediates—succinate, fumarate and
2-hydroxyglutarate (2-HG), respectively. They are known as oncometabolites, because of
their role in cancer growth, aggressiveness and progression [12]. This review will describe
the current understanding of oncometabolite role in cancer aggressiveness, with a special
emphasis on drug resistance. Next, we will focus on potential pharmacological strategies
targeting the production of oncometabolites as potential tools improving the efficacy of
anti-cancer treatments.
2. Mitochondrial Oncometabolites and Cancer Biology
Succinate, fumarate and 2-HG dysregulate a plethora of cellular processes associated
with invasiveness and drug resistance, such as protein post-translational modifications,
metabolic and epigenetic events, epithelial-to-mesenchymal transition (EMT), inhibition of
α-ketoglutarate (α-KG)-dependent dioxygenase enzymes [12]. Since α-KG is part of TCA
cycle, its modulation by the oncometabolites generated within the TCA cycle itself may
represent a finely tuned feedback control on the cycle itself.
Succinate is generated from succinyl-CoA and oxidated into fumarate by SDH. Fumarate
is the substrate for FH, an enzyme that catalyzes the reversible hydration/dehydration of fu-
marate to malate. SDH complex is built of four subunits (SDHA, SDHB, SDHC, SDHD). It is
the only TCA enzyme that produces FADH2 [12,13]. Mutations in SDH have been reported
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in all subunits. In addition, some SDH-deficient tumors either have hypermethylation
in the SDHC promoter, which phenotypically makes these tumors without a functioning
SDH [14] or have hyper-expressed the tumor necrosis factor-associated protein (TRAP1)
that inhibits SDH [15]. Moreover, down-regulation of SDH mRNA by miR-210, miR-31
and miR-37, post-translational modifications such as dephosphorylation by PTEN-like
mitochondrial phosphatase-1, deacetylation of lysines consequent to the loss of sirtuin
3, competitive inhibition by itaconate, a TCA cycle side-metabolite produced by the de-
carboxylation of cis-aconitate during inflammation [16], result in the inhibition of SDH
activity [17]. In all these cases succinate accumulates, as reported in paragangliomas,
pheochromocytomas, neuroblastomas [18], gastrointestinal stromal cancer [19], colon [20],
renal and ovarian cancers [21].
FH has isoforms with different cellular localization: one mitochondrial isoform partici-
pates in TCA cycle; one cytosolic isoform is involved in the metabolism of amino acids and
fumarate [22]. When FH is mutated, as described for instance in renal cell cancer (RCC) and
kidney renal papillary cell carcinoma (KIRP) [23], fumarate accumulates [13]. Importantly,
RCC with mutant FH is one of the most aggressive forms of renal cancer, characterized
by early metastasis and a poor clinical outcome [24]. Sporadic cases of deficient FH were
also reported for paragangliomas, pheochromocytomas [25], neuroblastoma [26], uterine
and skin leiomyoma [27], and endometrial cancer [28]. A similar metabolic phenotype
with fumarate accumulation is described in nasopharyngeal carcinomas overexpressing
the lymphoid-specific helicase, a chromatin remodeling ATPase that causes FH repression:
this phenotype has been linked to increased migration and invasion [29].
Differently from succinate and fumarate, 2-HG is produced by an abnormal catalytic
activity of IDH, a TCA enzyme that in physiological conditions catalyzes the decarboxy-
lation of isocitrate into α-KG and CO2, using NADP+ and Mg2+ as cofactors [30]. The
reverse reaction produces isocitrate through the reductive carboxylation of α-KG, consum-
ing NAD(P)H and CO2: when this reaction is incomplete and does not involve CO2, α-KG
is reduced into 2-HG [31]. IDH enzymes are present in three isoforms, each with a different
subcellular localization and co-substrates specificity: IDH1 is localized in peroxisomes
and cytosol and uses NADP+/NADPH, the NADP+/NADPH-dependent IDH2 and the
NAD+/NADH-dependent IDH3 are present in mitochondria. IDH1 reversibly intercon-
verts α-KG into isocitrate as part of the reductive glutamine metabolism [32]. IDH2 is
mainly involved in the oxidative metabolism of isocitrate in the TCA cycle, while IDH3
irreversibly oxidizes isocitrate to produce α-KG and NADH. Somatic point mutations
in IDH1 and IDH2 genes have been found in glioma, glioblastoma multiforme (GBM)
and acute myeloid leukemia (AML), prevalently concentrated in specific hot spots [30].
The IDH1 R132H/C/Q, IDH2 R140Q/W/L and R172K/M/G/T/S are the most common
mutations conferring a new catalytic activity with overproduction of 2-HG [33].
Succinate, fumarate and 2-HG contribute to cancer growth with pleiotropic mecha-
nisms, such as stabilization of the hypoxic inducible factor-1α (HIF-1α), epigenetic changes,
apoptosis alteration, increased production of mitochondrial ROS (mtROS) and protein
or chromatin “succinylation”, all events that occur often concurrently and are intercon-
nected [34].
The accumulation of succinate in tumors causes the so-called pseudohypoxia, a condi-
tion characterized by the stabilization of HIF-1α notwithstanding the normoxic environ-
ment. This pseudohypoxic phenotype promotes cell survival, proliferation, angiogenesis
and drug resistance [35]. Succinate mediates HIF-1α stabilization by inhibiting the prolyl-
hydroxylases (PHDs), which are responsible for hydroxylating HIF-1α and marking it
for proteasomal degradation. The mechanism of PHDs inhibition by succinate was first
demonstrated in HEK293 cells silenced for SDHD subunit that has increased succinate
and lacked HIF-1α degradation [36]. The same results were obtained in the human colon
cancer cell line HCT116, knocked-down for SDHB, where succinate accumulation and
HIF-1α stabilization were accompanied by lower mitochondrial O2 consumption rate
and higher extracellular acidification, indicative of a metabolic shift toward glycolysis
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induced by HIF-1α [37]. Succinate may act also through succinate receptor SUCNR1, which
stabilizes HIF-1α in non-small cell lung cancer by engaging the downstream mediators
phosphatidylinositol 3-phosphate kinase (PI3K)/Akt that phosphorylate HIF-1α on ser-
ine [38]. Of note, SUCNR1 is highly expressed also in kidney cancer, where its signaling
promotes angiogenesis, hematopoiesis and inflammation [39], and in tumor-associated
macrophages (TAMs), where the binding of succinate favors the polarization toward a
tumor-permissive M2-phenotype, facilitating cancer cell migration, invasion and metasta-
sis [38]. Further, the increase in mtROS that is associated with SDH deficiency [40] may
increase HIF-1α because ROS inactivate PHDs, thus preventing HIF-1α degradation [41,42].
In neuroblastoma, the increase of HIF-1α has also been caused by the inhibition of the
ten-eleven translocation proteins (TETs) that antagonize DNA methylation in specific loci
by oxidizing 5-methylcytosines. Both succinate and fumarate inhibited TETs and induced
the simultaneous transcriptional increase of HIF-1α and HIF-2α. However not all hypoxia-
responsive genes were upregulated [26], suggesting that differential circuitries—dependent
and independent from mitochondrial oncometabolites—control the transcriptional activity
of HIFs. In addition, 2-HG causes pseudohypoxia: in the presence of mutated IDH2, the
high ratio between 2-HG and α-KG reduces the activity of PHDs, stabilizing HIF-1α [33].
As mentioned before, mitochondrial oncometabolites cause epigenetic changes in
cancer cells, boosting oncogenesis and cancer progression. SDH deficient tumors are char-
acterized by hypermethylation of histones and DNA cytosine [14,43], as a result of the
succinate-mediated inhibition of histone lysine demethylases (KDMs) and TETs [26,44].
The hypermethylation changes the expression profile of specific genes, leading for in-
stance to the activation of the EMT program, as demonstrated in pheochromocytomas
and paragangliomas knocked-down for SDHB [45]. Moreover, fumarate inhibits TETs and
KDMs, suppressing the anti-metastatic miR-200, up-regulating specific transcription fac-
tors, such as Twist and HIF-1α, that promote EMT. As proof of concept, the reintroduction
of full-length Fh1 in mouse and human FH-deficient cells was sufficient to prevent the
EMT signature, reducing vimentin and restoring E-cadherin expression [46]. In addition,
epigenetic changes in FH deficient cells can contribute to defects in DNA Damage Response
(DDR) and to the bypass of the cell cycle checkpoints activated after DNA damage, e.g.,
after irradiation. In vitro studies on RCC-derived cell lines showed that FH deficiency
causes either the arrest in G1-phase or the more rapidly progress through mitosis after DNA
damage. Fumarate accumulation enhances the bypass of G2-phase checkpoints, activates
the error-prone non-homologous end-joining (NHEJ) repair system during cell mitosis,
and favors the accumulation of ROS, known inducers of DNA damage, with the result
of an increased genome instability [47]. The effects of fumarate in chromatin remodeling
and DNA damage are not tumor specific, because the DNA hypermethylation observed
in HepG2 cells exposed to millimolar concentrations of fumarate were comparable to the
hypermethylation detected in FH deficient cells [48]. Of note, hypermethylation can be
also caused by 2-HG that acts at the epigenetic level by competitively inhibiting TET2 and
JMJD2A/lysine demethylase 4A [33].
FH plays a physiological role in controlling cell proliferation, independent on the
effects on cell cycle and chromatin remodeling. This role is often altered in cancer cells, as
a consequence of the activation of other pathways peculiar of transformed cells, such as
the O-glycosylation (O-GlcNAc) pathway or the p21 Activated Kinase 4 (PAK4)-dependent
activity. While in non-transformed cells, FH binds the Activation Transcription Factor
2 (ATF2) and enhances its transcriptional activity, favoring cell cycle arrest, in cancer
cells, particularly in those tumors that display a high activity of O-GlcNAc transferase
(OGT) such as pancreatic adenocarcinoma (PDAC) [49], the FH/ATF2-mediated events are
impaired by the O-GlcNAc glycosylation of FH. This post-translational modification limits
the interaction between FH and ATF2, maintaining high levels of cell proliferation [50].
Accordingly, PDAC patients with high OGT and O-GlcNAc-FH levels have a lower median
survival [50]. Transforming growth factor β (TGFβ) is responsible for a second mechanism
of fumarate-dependent inhibition of cell proliferation, disrupted in cancer cells. TGFβ
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signaling favors growth arrest by increasing the phosphorylation of FH on Thr90 by p38
mitogen activated kinase (MAPK). Such phosphorylation favors the interaction between
FH and recombination signal binding protein for immunoglobulin kappa J region, also
known as CSL, a downstream effector of Notch. The FH/CSL complex associates p53
and is recruited on the promoter of the p53-targeted gene p21/cyclin dependent kinase
inhibitor 1A, which prevents cell cycle progression. PAK4, highly expressed in lung
cancers, counteracts the anti-proliferative effect induced by TGFβ/FH/CSL cascade by
phosphorylating FH on Ser46, an event that—contrarily to the phosphorylation on Thr90—
impairs the interaction between FH and CSL, favoring tumor proliferation and metastasis.
Conversely, the PAK4 inhibitor PF-3758309 favors the FH-CSL interaction in non-small cell
lung cancer cells and enhances the anti-proliferative effect induced by TGFβ [51].
Multiple pathways regulating cell proliferation and/or inhibiting of apoptosis are
controlled also by 2-HG [31]. In IDH1-R132Q knock-in mutant cells, 2-HG physically binds
Cdc42, a small GTPase of Rho family involved in the regulation of cell cycle. By doing so,
2-HG blocks Cdc42 interaction with mixed lineage kinase 3 (MLK3), a component of the
pro-apoptotic cascade MLK3/MKK4-7/JNK/Bim. Typically, 2-HG prevents the association
between Cdc42 and MLK3, preventing apoptosis and favoring cancer cells proliferation
and tumor mass expansion [52]. Moreover, it has been reported an important decrease
of p53 in mouse embryonic fibroblasts and HCT116 cells carrying IDH1-R132Q/R132H
mutations: the high levels of 2-HG stabilize HIF-2α, which activates the transcription of
miR-380-5p. The latter triggers the degradation of p53 mRNA, favoring cell proliferation
and tumorigenesis [30]. In agreement, the levels of p53 are negatively correlated with
IDH1-R132H levels in human gliomas [30], supporting at clinical levels the molecular
mechanism dependent on the 2-HG/HIF-2α/miR-380-5p axis described in vitro. A p53-
independent mechanism by which 2-HG prevents apoptosis has been documented in AML
cells engineered to express mutant IDH1-R132H, where 2-HG accumulates and inhibits the
cytochrome c oxidase complex of the ETC. This metabolic shut down increases the activa-
tion of the anti-apoptotic BCL2 protein, promoting tumor growth and progression [33,53],
likely by reducing mtROS.
A peculiar mechanism that links the production of TCA-derived oncometabolites to
oncogenesis and tumor progression is proteins succinylation, a post-translational modifica-
tion in which succinyl group is added to a lysine residue. After the attachment of succinate,
the positive charge of lysine is negatively charged, leading to important changes in protein
structure and function. Although hyper-succinylated proteins have been already associated
with the tumors with SDH, FH and IDH deficiency, the impact of this post-translational
modification in cancer cells is still matter of investigation [54]. The best studied protein
regulated by succinylation is Kelch-like ECH-associated protein 1 (KEAP1), the endoge-
nous inhibitor of the redox-sensitive transcription factor Nuclear Factor, Erythroid 2 Like 2
(NRF2). KEAP1 succinylation prevents its binding to NRF2, activating the NFR2-mediated
transcriptional program, including several genes involved in the antioxidant response [55].
Interestingly, the hyper-succinylation of several mitochondrial proteins in SDH and IDH
deficient cells may alter mitochondrial-dependent apoptosis and metabolism. For instance,
hyper-succinylated proteins in mitochondria increase the association of the pro-survival
BCL-2 protein to the mitochondrial membrane [56], a condition that confers resistance to
apoptosis. An intriguing cross-talk occurs between the three enzymes of TCA cycle pro-
ducing oncometabolites in glioma with mutated IDH1. Since 2-HG is a structural analogue
of succinate and fumarate it may inhibit both SDH and FH, determining the concurrent
accumulation of succinate and fumarate, the consequent hyper-succinylation of several pro-
teins and the inhibition of apoptosis. In line with this data, the reduction of succinylation,
obtained by overexpressing the desuccinylase SIRT5 in IDH1-R132C-harboring HT1080
cells, decreases BCL-2 accumulation and slows tumor growth [7,56]. Interestingly, protein
succinylation and epigenetic changes are two events strictly interconnected in tumors with
high levels of mitochondrial oncometabolites. Histones have about 30% lysine targets of
succinylation. Notably, histone and chromatin succinylation have been correlated with an
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increased transcription of the succinylated gene [34], although the detailed mechanisms
of how histone and non-histone protein succinylation affects tumorigenesis are still un-
explored [19]. The main effects of oncometabolites on cancer biology are summarized in
Figure 1.
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3. Mitochondrial Oncometabolites and Drug Resistance
The first indirect indication linking mitochondria-derived oncometabolites and drug
resistance is that tumors producing high amounts of oncometabolites are characterized
by highly aggressive phenotype and poor prognosis. Indeed, SDH deficiency is found
in about 5–10% of gastrointestinal stromal tumors, which affect younger patients, are
resistant to tyrosine kinase inhibitors and have a higher recurrence rate after surgical
resection [14]. A similar phenotype characterizes extra-adrenal paragangliomas with by
SHD mutations that have early onset, high aggressiveness and poor prognosis [57]. A
poor survival has also been observed in patients affected by KIRP with FH deficiency,
where FH levels are positively correlated with overall survival. The poor prognosis in
FH deficient tumors is explained by the down-regulation of the anti-metastatic miR-200a
and miR-200b, and by the activation of the EMT program [46,48]. In line with these
data, the analysis of kidney renal clear cell carcinoma (KIRC) TCGA database, showed
that the levels of FH mRNA and protein negatively correlate with vimentin, positively
correlate with E-cadherin and patients’ survival, confirming the role of FH loss in tumor
malignancy and patient poor outcome [46]. Moreover, fumarate accumulation is linked
with endometrial cancer aggressiveness, via adenylosuccinate lyase (ADSL) and killer cell
lectin-like receptor C3 (KLRC3): the knock-down of ADSL decreases KLRC3 that in turn
reduces cell proliferation, migration and invasion. Fumarate recovers KLRC3 expression
i ADSL-knock d dow cells, counteracting these anti-tumor effects a d contributing
to cancer aggressiveness [28]. Accordingly, in GBM, a tumor wh re oncometab lites are
often increased, the fumarate-dependent increase of KLRC3 has been correlated with radio-
resistance and poor outcome [58]. FH deficiency also protects cancer cells from drugs
targeting mitochondrial ETC and causing a metabolic catastrophe, as demonstrated in
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FH-deficient UOK262 cells treated with ONC201 [59], an anti-GBM agent that decreases
OXPHOS-mediated production of ATP [60].
In contrast with the finding suggesting that fumarate facilitates tumor aggressiveness
and resistance, in HeLa cells the increase of fumarate and malate chemosensitizes to
cisplatin, as demonstrated by slower cell proliferation and reduced tumor size in mice.
However, in this work the increase of fumarate seemed a consequence of the decreased
level of adenylate kinase 4, a key enzyme in regulating the high-energy phosphoryl transfer
reactions, rather than a deficiency of FH [61]. This discrepancy leads to hypothesize that a
TCA-independent increase of fumarate may have opposite effects than a TCA-dependent
increase in terms of chemotherapy efficacy.
Succinate is linked to chemoresistance because it stabilizes HIF-1α, a transcription
factor with a known role in drug resistance. First, as a consequence of the metabolic shift
toward a more glycolytic and acidic TME, HIF-1α inactivates weak bases chemotherapeutic
agents as anthracyclines. Moreover, it stimulates angiogenesis and EMT program, and
increases several drug efflux transporters, such as P-glycoprotein, multidrug resistance-
related protein 1 (MRP1) and breast cancer resistance protein [35]. Considering the plethora
of chemotherapeutic drugs effluxed by these transporters, tumors with high levels of HIF-
1α stabilized by succinate are characterized by a multidrug resistant phenotype. Lastly,
the hyper-succinylation increases also NRF2 that protects tumors from the chemotherapy-
induced oxidative damages by upregulating anti-oxidant enzymes, drug-inactivating
enzymes and MRP1 [62].
IDH1/IDH2-mutated tumors are also resistant to a plethora of drugs. One of the
most promising drugs for the treatment of refractory or relapsed AML is enasidenib/AG-
221, a IDH2 inhibitor [60]. However, two mutations of IDH2 in the wild-type allele,
specifically Q316E and I319M, induce resistance to enasidenib because they alter the
binding site between the drug and the IDH2 dimer. The presence of these mutations in
trans with the R140Q gain-of-function mutation on the second allele further enhances
the resistance to enasidenib [63]. Some cases of resistance to IDH-targeting therapies,
such as enasidenib/AG-221 for IDH2 or ivosidenib/AG-120 for IDH1, are caused by an
isoform switch induced by the treatment that shifts the prevailing isoform between the
cytoplasmic mutant IDH1 and the mitochondrial mutant IDH2. This switch has been
reported in a four-case study, and in chondrosarcoma cells harboring the double mutations
IDH1-R132G/IDH2-R172V and IDH1-R132H/IDH2-R172S. In these situations, the selective
pressure caused by the treatment with a single IDH inhibitor confers a growth advantage to
the subclones with prevalent activity of the IDH isoform not inhibited by the treatment [64].
This process is at the basis of the acquired resistance towards IDH-inhibitors and is common
particularly in hematological cancers, where IDH1 and IDH2 mutations often co-exist. The
use of the combined IDH1 and IDH2 inhibitors may likely prevent the onset of resistance
due to the IDH isoform switch. However, this approach has the risks of undesired toxicity
and unexpected drug-drug interaction.
IDH mutations confer the resistance also to other anti-cancer agents different from
IDH inhibitors. In solid tumors like GBM, IDH1 mutations prevail and confer not only
drug resistance but also radioresistance, because of the increased activity of DDR systems
and the high activity of de novo and salvage pathways of nucleotide synthesis [65]. GBM
cells carrying the R132H-IDH1 are specifically resistant to histone deacetylase inhibitors
(HDACi), such as trichostatin A, vorinostat and valproic acid as a consequence of the 2-
HG-induced transcriptional increase of NANOG [66], a key regulator of stemness and self-
renewal properties of cancer cells. Mechanisms oncometabolites mediated drug resistance
are summarized in Figure 2.




Figure 2. Effects of oncometabolites in drug resistance. The accumulation of oncometabolites such 
as succinate, fumarate and 2-hydroxyglutarate (2-HG) activates different mechanisms leading to 
drug resistance such as stabilization of hypoxia inducible factor-1α (HIF-1α), downregulation of 
anti-metastatic and oncosuppressor miRNAs, induction of epithelial-mesenchymal transition 
(EMT), overexpression of nuclear factor erythroid 2-related factor 2 (NRF2) and of the killer cell 
lectin like receptor C3 (KLRC3), prevention of the damages elicited by electron transport chain 
(ETC)-targeting agents, switch between isocitrate dehydrogenase (IDH) 1 and 2, activation of the 
stemness regulator NANOG. 
4. Pharmacological Approaches to Reduce Mitochondrial Oncometabolites 
On the one hand the metabolic re-arrangements of cancer cells with over-production 
of TCA-derived oncometabolites increase tumor aggressiveness; on the other hand, these 
tumors expose some metabolic vulnerabilities, offering new therapeutic opportunities to 
eradicate the cells over-producing oncometabolites (Table 1; Figure 3). 
Since succinate and fumarate accumulation mainly derive from loss-of-function mu-
tations in SDH and FH, a genetic correction reintroducing the deficient gene is still chal-
lenging and poorly feasible. Most attempts to counteract succinate and fumarate accumu-
lation target the downstream pathways activated by these oncometabolites. Indeed, as 
shown in SDHB knocked-out cells, cells with deficient SDH become extremely dependent 
on the oxidative glutaminolysis to meet their energy requirement. Therein, they are selec-
tively killed by the glutaminase 1 inhibitors compound 968 and CB-839 [37]. Similarly, 
also the bromodomain proteins inhibitor JQ1 displays a high selectivity against SDH de-
ficient cells, because it down-regulates c-Myc which transcriptionally enhances glutami-
nolysis enzymes [37]. Targeting glutaminolysis or its controllers is therefore an effective 
strategy to eradicate succinate hyper-producing cells. Succinate accumulation caused by 
SDH deficiency inhibits pyruvate dehydrogenase and stabilizes HIF-1α, but these effects 
are counteracted by exogenous αKG. The latter appeared indeed an effective antitumor 
and antiangiogenic compound in SHD-deficient tumors [67–69]. Moreover, since HIF-1α 
is activated by succinate, the use of HIF-1α inhibitors has been proposed as an alternative 
and effective strategy to block the tumor progression driven by succinate [36]. The major 
limitations to the use of HIF-1α inhibitors in patients are the high side-effect toxicity, due 
to the inhibition of the physiological functions of HIF-1α, and the limited anti-tumor effi-
cacy, likely because several downstream effectors of HIF-1α become independent drivers 
of oncogenesis and progression (https://clinicaltrials.gov/ct2/results/details?cond=Can-
cer&term=HIF), accessed on April 2021. 
Differently from succinate and fumarate, the accumulation of 2-HG may be overcome 
by the inhibition of mutated IDH. The first drug introduced against IDH mutated AML, 
venetoclax, was not a direct inhibitor of IDH, but it inhibited the anti-apoptotic protein 
BCL-2, which is increased by 2-HG [33,53]. After venetoclax, several direct inhibitors of 
IDH have been tested in clinical trials to antagonize 2-HG, but only two of them—
Succinate Fumarate 2-HG
➔ Downregulation of anti-
metastatic miRNAs
➔ Activation of the EMT program 
➔ Increase of KLRC3
➔ Prevention of ETC targeting-
agents inducing damage
➔ HIF-1α stabilization
➔ Activation of the EMT program 
➔ Increase of NRF2
➔ HIF-1α stabilization
➔ Activation of the EMT program 
➔ IDH1/2 switch
➔ Increased transcriptional 
activation of NANOG
DRUG RESISTANCE DRUG RESISTANCE DRUG RESISTANCE
Figure 2. Effects of oncometabolites in drug resistance. The accumulation of oncometabolites such
as succinate, fumarate and 2-hydroxyglutarate (2-HG) activates different mechanisms leading to
drug resistance such as stabilization of hypoxia inducible factor-1α (HIF-1α), downregulation of
anti-metastatic and oncosuppressor i s, i cti f it li l- s c l tr sition (EMT),
overexpr ssion of nuclear factor erythroid 2-related factor 2 (NRF2) and of the killer cell ectin
like rec ptor C3 (KLRC3), preventio of the dam ges licited by electron transport chain (ETC)-
targeting agents, switch between isocitrate dehydrogenase (IDH) 1 and 2, activation of the stemness
regulator NANOG.
4. Pharmacological A proaches to Reduce Mitochondrial Oncometabolites
On the one hand the metabolic re-a rangements of cancer cells with over-production
of TCA-derived oncometabolites increase tumor a gre sivene s; on the other hand, these
tumors expose some metabolic vulnerabilities, offering new therapeutic opportunities to
eradicate the cells over-producing oncometabolites (Table 1; Fig re 3).
Pharmaceutics 2021, 13, x  10 of 15 
 
 
daunorubicin [79]. This example shows that oncometabolites cannot be considered en-
tirely under a negative light, because high levels of 2-HG may exert anti-tumor and 
chemosensitizing effects in IDH1/IDH2 mutated GBM. 
It remains t  b cl rified, however, which factor b tween the l vel of oncometabolites 
or the oncogenic/oncosuppr ssor pathways al ered by mutated TCA e zymes play the
mos  promin nt role in che osensization or chemoresista ce. 
 
Figure 3. Overview of the main pharmacological strategies to prevent the synthesis and the effects 
of oncometabolites. Different pharmacological strategies are currently being investigated to coun-
teract the action of oncometabolites. Some of them t rget the enzy e that pr duces the on-
cometabolites, as isocitrate dehydrogenase (IDH) inhibitors, while others target the downstream 
effects of oncometabolites, such as glutaminolysis, pseudohypoxia or epigenetic changes. Differ-
ently, other approaches aim at competing with the oncometabolites themselves, such as the ad-
ministration of exogenous α-ketoglutarate (α-KG). (*) Gain-of-function mutations in isocitrate de-
hydrogenase (IDH); (X) loss-of-function mutations in succinate dehydrogenase (SDH) and 
fumarate hydratase (FH). 
5. Conclusions 
The involvement of mitochondria metabolism in cancer growth, progression and 
drug resistance has been established since a long time. However, many processes related 
to mitochondrial metabolic reprogramming and linked to drug resistance still need to be 
explored in depth. Among them, great attention has been recently paid to the mechanisms 
underlying aggressiveness and drug resistance associated with defects of SDH and FH, 
and hyper-activating mutations of IDH, all leading to the accumulation of mitochondrial 
oncometabolites. The generation of a pseudohypoxic phenotype, the epigenetic changes 
and the post-translational modification in specific proteins induced by the oncometabo-
lites have been regarded as the main mechanism promoting cancer progression. The 
mechanisms behind the drug resistance displayed by tumors with high levels of succinate, 
fumarate and 2-HG are in part similar. For instance, oncometabolite-induced resistance 
often relies on the oncometabolite-driven activation of HIF1-α and EMT programs. On-
cometabolites also specifically modulate oncogenic and/or oncosuppressor pathways, de-
termining a complex crosstalk between different genetic alterations co-existing in the 
same tumors, contributing to aggressiveness and resistance. 
Cells dependency on oxidative 
glutaminolysis
SDH IDH*FH
Fumarate   Su cinate    2-HG
Glutaminase inhibitors
IDH inhibitors
Oncometa olites compe itors 
(exogenous α-KG)
Pseudohypoxia HIF-1α inhibitors 
Epigenetic changes
Demethylating agents, DNA 
methyltransferase inhibitors,
Bromodomain inhibitors 
Figure 3. Overview of the main pharmacological strategies to prevent the synthesis and the effects of
oncometabolites. Different pharmacological strategies are currently being investigated to counteract
the action of oncometabolites. Some of them target the enzyme that produces the oncometabo-
lites, as isocitrate dehydrogenase (IDH) inhibitors, while others target the downstream effects of
oncometabolites, such as glutaminolysis, pseudohypoxia or epigenetic changes. Differently, other
appro ches im at competing with the oncometabolites th ms lves, such as the administration of
exogen us α-k t glutarate (α-KG). (*) Gain-of-function m ta s in isocitrate dehydrogenase (IDH);
(X) loss-of-function mutations in succinate dehydrogenase (SDH) and fumarate hydratase (FH).
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Since succinate and fumarate accumulation mainly derive from loss-of-function muta-
tions in SDH and FH, a genetic correction reintroducing the deficient gene is still challeng-
ing and poorly feasible. Most attempts to counteract succinate and fumarate accumulation
target the downstream pathways activated by these oncometabolites. Indeed, as shown in
SDHB knocked-out cells, cells with deficient SDH become extremely dependent on the ox-
idative glutaminolysis to meet their energy requirement. Therein, they are selectively killed
by the glutaminase 1 inhibitors compound 968 and CB-839 [37]. Similarly, also the bromod-
omain proteins inhibitor JQ1 displays a high selectivity against SDH deficient cells, because
it down-regulates c-Myc which transcriptionally enhances glutaminolysis enzymes [37].
Targeting glutaminolysis or its controllers is therefore an effective strategy to eradicate
succinate hyper-producing cells. Succinate accumulation caused by SDH deficiency in-
hibits pyruvate dehydrogenase and stabilizes HIF-1α, but these effects are counteracted
by exogenous αKG. The latter appeared indeed an effective antitumor and antiangiogenic
compound in SHD-deficient tumors [67–69]. Moreover, since HIF-1α is activated by succi-
nate, the use of HIF-1α inhibitors has been proposed as an alternative and effective strategy
to block the tumor progression driven by succinate [36]. The major limitations to the
use of HIF-1α inhibitors in patients are the high side-effect toxicity, due to the inhibition
of the physiological functions of HIF-1α, and the limited anti-tumor efficacy, likely be-
cause several downstream effectors of HIF-1α become independent drivers of oncogenesis
and progression (https://clinicaltrials.gov/ct2/results/details?cond=Cancer&term=HIF),
accessed on April 2021.
Differently from succinate and fumarate, the accumulation of 2-HG may be overcome
by the inhibition of mutated IDH. The first drug introduced against IDH mutated AML,
venetoclax, was not a direct inhibitor of IDH, but it inhibited the anti-apoptotic protein
BCL-2, which is increased by 2-HG [33,53]. After venetoclax, several direct inhibitors
of IDH have been tested in clinical trials to antagonize 2-HG, but only two of them—
enasidenib/AG-221 and ivosidenib/AG-120—have been approved for the treatment of
refractory AML [70]. Enasidenib is a small molecule inhibiting mutant IDH2, which is
overexpressed in hematological cancers: it has high selectivity, good solubility and oral
bioavailability [33]. Ivosidenib, also characterized by good oral bioavailability, shows a
preferential inhibition on IDH1 and is evaluated for solid tumors including GBM [33]. Since
in some cases the tumors display the shift between IDH1 and IDH2 mutant isoforms, mak-
ing isoform-selective inhibitors progressively ineffective [64], dual IDH1/IDH2 inhibitors
are under evaluation. One of the most promising dual inhibitors is vorasidenib, and has
been proposed for the treatment of GBM since it is able to cross the blood brain barrier [71].
Importantly, the response to IDH inhibitors is affected by the type of mutations [72]. In-
deed, it has been demonstrated that R132Q mutation alters the catalytic site structure in
such a way that the IDH1 inhibitors ML309, AGI-5198 and GSK864 are less potent. By
contrast they are instead more active against R132H-IDH1 or wild-type IDH1 expressing
cells [72]. This aspect must be carefully considered in choosing the right inhibitor for the
right mutant tumor.
Besides specific inhibitors, several miRNA-targeting agents are also considered since
it has been clearly demonstrated that miR-181a had inhibitory effect on IDH1 and miR-
183 on IDH2 [73,74]. However, despite the promising results obtained in vitro and in
preclinical models, miRNA technology is still problematic in clinical use. Therefore, its
efficacy in targeting IDH1/IDH2 activated tumors must be re-evaluated when technical
issues concerning delivery, stability and specificity will be overcome.
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Table 1. Main pharmacological approaches counteracting oncometabolites effects on cancer progres-
sion and drug resistance.
Targeted Oncometabolite Mutated Gene Drugs















2-HG: 2-hydroxyglutarate; SDH: succinate dehydrogenase; FH: fumarate dehydratase; IDH: isocitrate dehydroge-
nase; αKG: α-ketoglutarate; HIF-1α: hypoxia-induced transcriptional factor.
Notably, IDH mutant tumors are characterized by hyper-methylation of DNA, as a
result of the epigenetic changes induced by TCA-derived oncometabolites [12]. Hence,
some demethylating agents are under investigation in IDH mutated tumors. For instance,
the DNA methyltransferase inhibitors azacytidine and decitabine have showed clinical
benefits in AML, including IDH mutated leukemias [75,76]. Interestingly, IDH1 and IDH2
mutated GBM, SDHB deficient pheochromocytoma and paraganglioma are more sensitive
to temozolomide (TMZ), and IDH1/2 mutations are con-sidered a good prognostic factor.
This is likely explained by the hypermethylation of the O6-methylguanine DNA methyl-
transferase promoter, one of the key antagonists of TMZ activity, in mutated tumors [77,78].
Consistently, the exposure of GBM cells to exogenous 2-HG slows down tumor progression
and has a synergistic effect with chemotherapeutic agents inhibiting DNA demethyla-
tion, such as azacytidine and decitabine, or inducing DNA damage as daunorubicin [79].
This example shows that oncometabolites cannot be considered entirely under a negative
light, because high levels of 2-HG may exert anti-tumor and chemosensitizing effects in
IDH1/IDH2 mutated GBM.
It remains to be clarified, however, which factor between the level of oncometabolites
or the oncogenic/oncosuppressor pathways altered by mutated TCA enzymes play the
most prominent role in chemosensization or chemoresistance.
5. Conclusions
The involvement of mitochondria metabolism in cancer growth, progression and drug
resistance has been established since a long time. However, many processes related to
mitochondrial metabolic reprogramming and linked to drug resistance still need to be
explored in depth. Among them, great attention has been recently paid to the mechanisms
underlying aggressiveness and drug resistance associated with defects of SDH and FH, and
hyper-activating mutations of IDH, all leading to the accumulation of mitochondrial on-
cometabolites. The generation of a pseudohypoxic phenotype, the epigenetic changes and
the post-translational modification in specific proteins induced by the oncometabolites have
been regarded as the main mechanism promoting cancer progression. The mechanisms
behind the drug resistance displayed by tumors with high levels of succinate, fumarate and
2-HG are in part similar. For instance, oncometabolite-induced resistance often relies on
the oncometabolite-driven activation of HIF1-α and EMT programs. Oncometabolites also
specifically modulate oncogenic and/or oncosuppressor pathways, determining a complex
crosstalk between different genetic alterations co-existing in the same tumors, contributing
to aggressiveness and resistance.
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To slow down tumor progression and improve drugs sensitivity, different therapeutic
strategies targeting the mitochondria-derived oncometabolites have been experimented,
and some of them reached phase I/II clinical trials. This is the situation of tumors with
IDH1/IDH2 mutations that can be treated with small molecules acting as selective in-
hibitors, with good success in AML and GBM. Since the defects related to SDH and FH
are prevalently due to loss of function, the direct targeting of these enzyme with specific
activators or with genetic engineering is more difficult. A better strategy, although indi-
rect, is interfering with the pathways activated by succinate and fumarate. Inhibitors of
EMT program, which is downstream of all three TCA-derived oncometabolites—may be
another approach limiting tumor aggressiveness, invasion and chemoresistance. In this
perspective, epigenetic drugs such as demethylating agents and DNA methyltransferase
inhibitors that have been demonstrated to block EMT program [80] are of particular interest.
Indeed, IDH1 mutants GBM are resistant to HDACi [66]. The combination of the IDH1
inhibitors ivosidenib/AG-120 associated with other epigenetic drugs such as decitabine or
azacytabine, may open new therapeutic possibilities for aggressive and chemorefractory
tumors producing oncometabolites.
Another intriguing point is understanding the possible cross-talk between each on-
cometabolite produced within the tumor cell. If defective SDH and FH lead to the accu-
mulation of succinate and fumarate, this derangement of TCA flux can slow down the
upstream steps of the cycle. The accumulation of citrate and isocitrate may favor the
generation of 2-HG, thus generating tumors with all three oncometabolites increased. Con-
versely, a hyperactive/mutated IDH subtracts α-KG from the TCA cycle, and this diversion
can indirectly reduce the rate of downstream enzymes, thus limiting the production of
succinate and fumarate in tumors with wild-type SDH and FH. Of course, the presence
of defective forms of SDH and FH produces the accumulation of fumarate and succinate
also in case of mutated IDH. Different combination strategies, depending on the relative
amounts of 2-HG, fumarate and succinate, and on the activity of their downstream effectors,
should be adopted in order to maximize the efficacy of anti-oncometabolite agents.
Since several genetic lesions within a tumor may co-exist, an in-depth genomic pro-
filing of the TCA cycle genes may help identifying the TCA cycle genotypic profile and
the best choice of treatment. The presence of different clones within the same tumors,
harboring different mutations, further complicates the situation, because different areas
within the tumor bulk may behave metabolically differently. To partially circumvent this
issue, the coupling of high-throughput metabolomic analysis and high-resolution imag-
ing analysis by MALDI-imaging techniques can map the intratumor areas with different
levels of TCA cycle metabolism and identify the most prominent metabolic phenotype
within the tumor mass. The simultaneous advancement in diagnostic techniques and
oncometabolite-targeting agents will help the development of an “oncometabolite-based
precision medicine” in the next future.
Indeed, despite the limited number of drugs targeting the mitochondria-derived
oncometabolites currently available, the research in this field can open very interesting
therapeutic opportunities. First tumors with mutations in TCA offer the possibility of
targeting either the TCA cycle mutated enzymes or the downstream pathways controlled by
the oncometabolite, leading the way to different combination therapies that can be exploited
with anti-tumor, anti-metastatic or chemosensitizer purpose. Second, it is noteworthy that
the agents targeting the production of mitochondrial derived oncometabolite are rather
tumor-selective, because they hit isoforms of the TCA cycle enzymes detected in tumors,
but not in non-transformed cells. Therefore, the pharmacological development of these
drugs is particularly attractive, because it may lead to the realization of the first “metabolic
targeted therapy” in the oncological field, conceived as a multi-target therapy peculiarly
effective against tumors resistant to conventional treatments.
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